{"protocolSection": {"identificationModule": {"nctId": "NCT04092582", "orgStudyIdInfo": {"id": "GB41149"}, "secondaryIdInfos": [{"id": "2019-000795-41", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Genentech, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller", "officialTitle": "A Phase IIa, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-10-31", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-05-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-05-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-09-13", "studyFirstSubmitQcDate": "2019-09-13", "studyFirstPostDateStruct": {"date": "2019-09-17", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-05-11", "resultsFirstSubmitQcDate": "2023-08-11", "resultsFirstPostDateStruct": {"date": "2023-08-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-11", "lastUpdatePostDateStruct": {"date": "2023-08-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Genentech, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a Phase IIa, randomized, placebo-controlled, double-blind, multicenter, two-arm study to evaluate the efficacy, safety, and pharmacokinetics of MTPS9579A as an add-on therapy in patients with uncontrolled moderate to severe asthma who are receiving daily ICS therapy and at least one of the following additional controller medications: long-acting beta-agonist (LABA), leukotriene modulator (leukotriene modifier \\[LTM\\] or leukotriene receptor antagonist \\[LTRA\\]), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 135, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MTPS9579A", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MTPS9579A"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "MTPS9579A", "description": "MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.", "armGroupLabels": ["MTPS9579A"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Composite Asthma Exacerbations (CompEX) Event", "description": "CompEX is defined as time from randomization to first asthma exacerbation or diary worsening during the treatment period.\n\nAsthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that resulted in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Diary worsening is based on the occurrence of prespecified changes in the following six parameters: morning peak expiratory flow rate (PEFR), evening PEFR, morning symptom score, evening symptom score, morning short-acting rescue therapy use, and evening short-acting rescue therapy use. Hazard ratio was used for the analysis.", "timeFrame": "Randomization [Week 2] to end of treatment (EOT) [Week 50]"}], "secondaryOutcomes": [{"measure": "Rate of Asthma Exacerbations", "description": "The number of asthma exacerbations per year was reported for this outcome measure. Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that resulted in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Poisson regression was used for the analysis.", "timeFrame": "Randomization [Week 2] to Week 50"}, {"measure": "Time to First Asthma Exacerbation", "description": "The time from randomization to first asthma exacerbation was measured. Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that resulted in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Cox regression was used for the analysis.", "timeFrame": "Randomization [Week 2] to Week 50"}, {"measure": "Absolute Change From Randomization in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 50", "description": "FEV1 is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the absolute change pre-bronchodilator FEV1 as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FEV1 as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/microliter (uL)), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region.", "timeFrame": "Randomization [Week 2] to Week 50"}, {"measure": "Relative Percent Change From Randomization in Pre-Bronchodilator FEV1 at Week 50", "description": "FEV1 was the volume of air exhaled in the first second of a forced exhalation as measured by spirometer. Measurements were performed before use of bronchodilator. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the relative change pre-bronchodilator FEV1 as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FEV1 as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/uL), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region. Relative change (%) in FEV1 = (absolute change in FEV1 / baseline FEV1) x 100.", "timeFrame": "Randomization [Week 2] to Week 50"}, {"measure": "Absolute Change From Randomization in Fractional Exhaled Nitric Oxide (FeNO) at Week 50", "description": "FeNO is a volatile marker of airway inflammation that decreases with inhaled corticosteroid treatment. The measurements recorded were according to standardized procedures by the American Thoracic Society. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the absolute change pre-bronchodilator FeNO as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FeNO as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/uL), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region.", "timeFrame": "Randomization [Week 2] to Week 50"}, {"measure": "Relative Percent Change From Randomization in FeNO at Week 50", "description": "FeNO is a volatile marker of airway inflammation that decreases with inhaled corticosteroid treatment. The measurements recorded were according to standardized procedures by the American Thoracic Society. Relative change (%) in FeNO = (absolute change in FeNO / baseline FeNO) x 100. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the absolute change pre-bronchodilator FeNO as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FeNO as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/uL), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region.", "timeFrame": "Randomization [Week 2] to Week 50"}, {"measure": "Percentage of Participants With Adverse Events", "description": "An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.", "timeFrame": "Up to approximately Week 58"}, {"measure": "Area Under Concentration-Time Curve for the First Dosing Interval (AUClast) of MTPS9579A", "timeFrame": "Randomization [Week 2] to Week 6"}, {"measure": "Maximum Serum Concentration (Cmax) for the First Dosing Interval of MTPS9579A", "timeFrame": "2-hour post-dose on Week 2"}, {"measure": "Steady State Cmax of MTPS9579A", "timeFrame": "2-hour post-dose on Week 14"}, {"measure": "Maximum Time to Serum Concentration (Tmax) of MTPS9579A", "timeFrame": "Pre-dose and 2-hour post-dose on Week 2"}, {"measure": "Trough Serum Concentration (Ctrough) Accumulation Ratio of MTPS9579A", "description": "The accumulation ratio is calculated by taking the individual ratio of the Ctrough at Week 14 to the Ctrough at Week 6.", "timeFrame": "Predose on Weeks 6 and 14"}, {"measure": "Steady State Ctrough of MTPS9579A", "timeFrame": "Pre-dose on Week 14"}, {"measure": "Percentage of Participants With Anti-Drug Antibodies (ADA) to MTPS9579A", "description": "Treatment Emergent ADA is (a) negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result, OR (b) positive ADA result at baseline and one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result.", "timeFrame": "Pre-dose Week 54"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Documented physician-diagnosed asthma for at least 12 months prior to screening\n* Treatment with asthma controller therapy (daily ICS \\[fluticasone propionate or equivalent\\] and at least one additional controller therapy \\[LABA, LAMA, LTM/LTRA\\]) for \\>= 3 months prior to screening, with no changes within 4 weeks prior to screening or during the screening period and no anticipated changes in controller dosing regimens throughout the study\n* Documented history of \\>= 2 asthma exacerbation within the 12 months prior to screening while on daily ICS maintenance therapy\n* For women of childbearing potential: agreement to remain abstinent or use contraception For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm\n\nExclusion Criteria:\n\n* History or evidence of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation associated with panic attacks, or other mimics of asthma\n* History or evidence of significant respiratory disease other than asthma, including occupational asthma, aspirin-sensitive asthma, asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome, bronchiolitis, interstitial lung disease, or COPD\n* Current smoker, electronic cigarette (e-cigarette) user, former smoker with smoking history of \\> 10 pack-years, former e-cigarette user with an e-cigarette history of at least daily use for \\>=10 years, or unwilling to abstain from smoking and/or e-cigarette use from the time of consent through the completion of the study\n* History or evidence of any clinically significant medical condition/disease or abnormalities in laboratory tests that, in the investigator's judgment, precludes the patient's safe participation and completion of the study, or interferes with the conduct and interpretation of the study\n* Active malignancy or history of malignancy within 5 years of screening, except for appropriately treated non-melanoma skin carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or Stage I uterine cancer\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of MTPS9579A\n* Positive for TB at screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Trials", "affiliation": "Hoffmann-La Roche", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Kern Research", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Allergy & Asthma Medical Group of the Bay Area", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Florida Ctr-Allergy & Asthma", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Florida Pulmonary Research Institute, LLC", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Toledo Inst of Clin Research", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "OK Clinical Research", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Temple University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Spartanburg Medical Research", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Fundacion Cidea", "city": "Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Centro M\u00e9dico Dra. Cristina de Salvo", "city": "Buenos Aires", "zip": "C1426ABO", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "CARE - Centro de Alergia y Enfermedades Respiratorias", "city": "Caba", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Centro Respiratorio Quilmes", "city": "Quilmes", "zip": "B1878FNR", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "Research Center for Medical Studies RCMS", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "IKF Pneumologie", "city": "Frankfurt am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Pneumologicum", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "BAG Prof Dr G Hoheisel Dr A Bonitz", "city": "Leipzig", "zip": "04275", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "SMO.MD GmbH, Zentrum f\u00fcr klinische Studien", "city": "Magdeburg", "zip": "39120", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "Clinica Providencia (Inverconsult Sociedad Anonima)", "city": "Lima", "zip": "32", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Clinica Ricardo Palma; THORAX", "city": "Lima", "zip": "Lima 27", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Centrum Medycyny Oddechowej Robert M. Mr\u00f3z", "city": "Bialystok", "zip": "15-003", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Centrum Medyczne ALL-MED", "city": "Krakow", "zip": "30-033", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Malopolskie Centrum Alergologii", "city": "Krakow", "zip": "30-727", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Ostrowieckie Centrum Medyczne Spolka Cywilna Anna Olec-Cudzik; Krzysztof Cudzik", "city": "Ostrowiec Swietokrzysk", "zip": "27-400", "country": "Poland"}, {"facility": "Centrum Alergologii Teresa Hofman", "city": "Poznan", "zip": "60-214", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "PULMAG Grzegorz Gasior Marzena Kociolek Spolka Cywilna", "city": "Sosnowiec", "zip": "41-200", "country": "Poland", "geoPoint": {"lat": 50.28682, "lon": 19.10385}}, {"facility": "ALL-MED Specjalistyczna Opieka Medyczna", "city": "Wroclaw", "zip": "50-445", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study included a 2-week single-blind placebo run-in period. A total of 135 participants were randomized in double-blind treatment period. Of the 135 participants randomized, 134 participants received at least one dose of study drug and their intended treatment.", "recruitmentDetails": "Participants took part in the study at 26 investigative sites in 5 countries (Argentina, Germany, Peru, Poland, and the United States) from 31 October 2019 to 19 May 2022.", "groups": [{"id": "FG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as intravenous (IV) infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "FG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "66"}]}, {"type": "Safety Population", "comment": "The safety analysis population included all randomized participants who received at least one dose of study drug during the 48-week double-blind treatment period.", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "65"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "64"}, {"groupId": "FG001", "numSubjects": "63"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Enrolled but Failed to Meet Randomization Criteria; Excluded from Study Analysis", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Modified Intent-to-Treat population (mITT) population included all randomized participants who received at least one dose of study treatment.", "groups": [{"id": "BG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A,1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "BG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "134"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.7", "spread": "12.0"}, {"groupId": "BG001", "value": "52.9", "spread": "13.2"}, {"groupId": "BG002", "value": "53.8", "spread": "12.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "73"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "61"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "22"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "112"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "121"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Composite Asthma Exacerbations (CompEX) Event", "description": "CompEX is defined as time from randomization to first asthma exacerbation or diary worsening during the treatment period.\n\nAsthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that resulted in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Diary worsening is based on the occurrence of prespecified changes in the following six parameters: morning peak expiratory flow rate (PEFR), evening PEFR, morning symptom score, evening symptom score, morning short-acting rescue therapy use, and evening short-acting rescue therapy use. Hazard ratio was used for the analysis.", "populationDescription": "Modified Intent-to-Treat population (mITT) population included all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "weeks", "timeFrame": "Randomization [Week 2] to end of treatment (EOT) [Week 50]", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "31.3", "upperLimit": "NA", "comment": "The data for median upper limit of confidence interval (CI) was not estimable due to insufficient number of participants with events."}, {"groupId": "OG001", "value": "45.4", "lowerLimit": "19.0", "upperLimit": "NA", "comment": "The data for upper limit of CI was not estimable due to insufficient number of participants with events."}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6835", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.90", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.55", "ciUpperLimit": "1.47"}]}, {"type": "SECONDARY", "title": "Rate of Asthma Exacerbations", "description": "The number of asthma exacerbations per year was reported for this outcome measure. Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that resulted in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Poisson regression was used for the analysis.", "populationDescription": "mITT population included all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Asthma exacerbations per patient-year", "timeFrame": "Randomization [Week 2] to Week 50", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.4689"}, {"groupId": "OG001", "value": "0.4267"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.7648", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.0989", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5925", "ciUpperLimit": "2.0381"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation", "description": "The time from randomization to first asthma exacerbation was measured. Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that resulted in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Cox regression was used for the analysis.", "populationDescription": "mITT population included all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "weeks", "timeFrame": "Randomization [Week 2] to Week 50", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The data for median, lower and upper limit of CI was not estimable due to insufficient number of participants with events."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The data for median, lower and upper limit of CI was not estimable due to insufficient number of participants with events."}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5248", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.43", "ciUpperLimit": "1.54"}]}, {"type": "SECONDARY", "title": "Absolute Change From Randomization in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 50", "description": "FEV1 is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the absolute change pre-bronchodilator FEV1 as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FEV1 as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/microliter (uL)), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region.", "populationDescription": "mITT population included all randomized participants who received at least one dose of study treatment. Overall number of participants analyzed are the number of participants available for analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Randomization [Week 2] to Week 50", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as intravenous (IV) infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "0.034"}, {"groupId": "OG001", "value": "0.03", "spread": "0.034"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1250", "statisticalMethod": "Mixed model for repeated measures (MMRM)"}]}, {"type": "SECONDARY", "title": "Relative Percent Change From Randomization in Pre-Bronchodilator FEV1 at Week 50", "description": "FEV1 was the volume of air exhaled in the first second of a forced exhalation as measured by spirometer. Measurements were performed before use of bronchodilator. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the relative change pre-bronchodilator FEV1 as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FEV1 as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/uL), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region. Relative change (%) in FEV1 = (absolute change in FEV1 / baseline FEV1) x 100.", "populationDescription": "mITT population included all randomized participants who received at least one dose of study treatment. Overall number of participants analyzed are the number of participants available for analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Randomization [Week 2] to Week 50", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.44", "spread": "1.894"}, {"groupId": "OG001", "value": "3.15", "spread": "1.921"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.2249", "statisticalMethod": "Mixed model for repeated measures (MMRM)"}]}, {"type": "SECONDARY", "title": "Absolute Change From Randomization in Fractional Exhaled Nitric Oxide (FeNO) at Week 50", "description": "FeNO is a volatile marker of airway inflammation that decreases with inhaled corticosteroid treatment. The measurements recorded were according to standardized procedures by the American Thoracic Society. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the absolute change pre-bronchodilator FeNO as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FeNO as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/uL), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region.", "populationDescription": "mITT population included all randomized participants who received at least one dose of study treatment. Overall number of participants analyzed are the number of participants available for analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "parts per billion (ppb)", "timeFrame": "Randomization [Week 2] to Week 50", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.67", "spread": "2.722"}, {"groupId": "OG001", "value": "-1.52", "spread": "2.791"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.9693", "statisticalMethod": "Mixed model for repeated measures (MMRM)"}]}, {"type": "SECONDARY", "title": "Relative Percent Change From Randomization in FeNO at Week 50", "description": "FeNO is a volatile marker of airway inflammation that decreases with inhaled corticosteroid treatment. The measurements recorded were according to standardized procedures by the American Thoracic Society. Relative change (%) in FeNO = (absolute change in FeNO / baseline FeNO) x 100. Estimates are based on a mixed model for repeated measures (MMRM) analysis with an unstructured covariance matrix. The model used the absolute change pre-bronchodilator FeNO as the response variable and included terms for treatment arm, study visit, treatment arm by study visit interaction, baseline FeNO as well as its interaction with study visit, in addition to the stratification factors: blood eosinophil level at visit 1 (\\<150, \\>=150 to \\<=300, \\>300 cells/uL), number of asthma exacerbations requiring the use of systemic corticosteroids within the 12 months prior to the study entry (1 or \\>=2 events), and geographic region.", "populationDescription": "mITT population included all randomized participants who received at least one dose of study treatment. Overall number of participants analyzed are the number of participants available for analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Randomization [Week 2] to Week 50", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.02", "spread": "10.223"}, {"groupId": "OG001", "value": "26.29", "spread": "10.482"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.9855", "statisticalMethod": "Mixed model for repeated measures (MMRM)"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Adverse Events", "description": "An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.", "populationDescription": "The safety analysis population included all randomized participants who received at least one dose of study drug during the 48-week double-blind treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Up to approximately Week 58", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79.7"}, {"groupId": "OG001", "value": "86.2"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Concentration-Time Curve for the First Dosing Interval (AUClast) of MTPS9579A", "populationDescription": "PK-evaluable population includes all participants who had at least one evaluable PK sample", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "day*ug/mL", "timeFrame": "Randomization [Week 2] to Week 6", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5263.14", "spread": "83.6"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Serum Concentration (Cmax) for the First Dosing Interval of MTPS9579A", "populationDescription": "PK-evaluable population includes all participants who had at least one evaluable PK sample.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ug/mL", "timeFrame": "2-hour post-dose on Week 2", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "419", "spread": "51.4"}]}]}]}, {"type": "SECONDARY", "title": "Steady State Cmax of MTPS9579A", "populationDescription": "PK-evaluable population includes all participants who had at least one evaluable PK sample", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ug/mL", "timeFrame": "2-hour post-dose on Week 14", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "735", "spread": "31.0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Time to Serum Concentration (Tmax) of MTPS9579A", "populationDescription": "PK-evaluable population includes all participants who had at least one evaluable PK sample.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "day", "timeFrame": "Pre-dose and 2-hour post-dose on Week 2", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "3.41"}]}]}]}, {"type": "SECONDARY", "title": "Trough Serum Concentration (Ctrough) Accumulation Ratio of MTPS9579A", "description": "The accumulation ratio is calculated by taking the individual ratio of the Ctrough at Week 14 to the Ctrough at Week 6.", "populationDescription": "PK-evaluable population includes all participants who had at least one evaluable PK sample.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ratio", "timeFrame": "Predose on Weeks 6 and 14", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.93", "spread": "28.3"}]}]}]}, {"type": "SECONDARY", "title": "Steady State Ctrough of MTPS9579A", "populationDescription": "PK-evaluable population includes all participants who had at least one evaluable PK sample.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ug/mL", "timeFrame": "Pre-dose on Week 14", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "226", "spread": "45.4"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Anti-Drug Antibodies (ADA) to MTPS9579A", "description": "Treatment Emergent ADA is (a) negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result, OR (b) positive ADA result at baseline and one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result.", "populationDescription": "The immunogenicity analysis population included all participants with at least one ADA assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Pre-dose Week 54", "groups": [{"id": "OG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}, {"id": "OG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "65"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.9"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to approximately Week 58", "description": "All cause mortality data was collected for all enrolled participants and serious adverse events (SAE) and other adverse events (AE) was collected for Safety analysis population. The safety analysis population included all randomized participants who received at least one dose of study drug during the 48-week double-blind treatment period.", "eventGroups": [{"id": "EG000", "title": "MTPS9579A, 1800 mg", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants then received MTPS9579A, 1800 mg, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46.", "deathsNumAffected": 1, "deathsNumAtRisk": 69, "seriousNumAffected": 5, "seriousNumAtRisk": 69, "otherNumAffected": 32, "otherNumAtRisk": 69}, {"id": "EG001", "title": "Placebo", "description": "Participants with uncontrolled moderate to severe asthma received Placebo, given as IV infusion, for 14 days in the Placebo run-in period. Participants received MTPS9579A matching placebo, given as IV infusion at randomization (Week 2), Week 6, and every 4 weeks thereafter through Week 46.", "deathsNumAffected": 1, "deathsNumAtRisk": 66, "seriousNumAffected": 4, "seriousNumAtRisk": 65, "otherNumAffected": 38, "otherNumAtRisk": 65}], "seriousEvents": [{"term": "Accidental death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "COVID-19 pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "Tendon injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}]}], "otherEvents": [{"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 65}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 65}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 65}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 65}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 31, "numAffected": 19, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 33, "numAffected": 24, "numAtRisk": 65}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version: 25.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 65}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Enrollment was halted on 08 April 2020 in response to the emerging pandemic and concerns regarding data integrity (e.g., missed study doses and visits). The trial was restarted on 22 June 2020."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."}, "pointOfContact": {"title": "Medical Communications", "organization": "Hoffmann-La Roche", "email": "genentech@druginfo.com", "phone": "800 821-8590"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-09-18", "uploadDate": "2023-05-11T06:04", "filename": "Prot_000.pdf", "size": 1895064}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-07-30", "uploadDate": "2023-05-11T06:04", "filename": "SAP_001.pdf", "size": 2474021}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-06-06", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}